Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …
Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.
Read more on PharmaceuticalOnline
Categories: Metastatic Breast Cancer Tags: combination, enrollment, initiate, Merrimack, MM121, Pharmaceuticals, Phase, SanofiAventis, Study